ALK and non-small cell lung carcinoma: Moreover, the phase II study PROFILE 1005 confirmed these outstanding results on 261 ALK-positive pre-treated NSCLC patients, showing an ORR of 59.8%, with a median duration of response of 45.6 weeks, and a median PFS of 8.1 months (95% CI 6.8–9.7).